Info

🌱來自: renal-cell-carcinoma

Combined-modality therapies-of-renal-cell-carcinoma

**1° endpoint(s) listed below include PFS &/or median OS Axitinib+avelumab (NEJM 2019; 380:1103) vs. sunitinib: PFS: 13.8 mos vs. 8.4 mos (HR: 0.69, P <0.001); OS for PD-L1-high 86.3% vs. 84.8% (HR for death: 0.82, P = 0.38) Axitinib+pembrolizumab (NEJM 2019;380:1116) vs. sunitinib: PFS: 15.1 mos vs. 11.1 mos (HR: 0.69, P <0.001); OS 89.9% vs. 78.3% (HR for death 0.53, P <0.0001) Cabozantinib+nivolumab (NEJM 2021;384:829) vs. sunitinib: PFS 16.6 mos vs. 8.3 mos (HR: 0.51, P <0.001) Lenvatinib+everolimus (NEJM 2021;384:1289) vs. sunitinib: PFS: 14.7 mos vs. 9.2 mos (HR: 0.65, P <0.001) Lenvatinib+pembrolizumab (NEJM 2021;384:1289) vs. sunitinib: PFS 23.9 mos vs. 9.2 mos (HR: 0.39, P <0.001)

Siblings

• Epidemiology-of-renal-cell-carcinoma
• Histology and molecular biology-of-renal-cell-carcinoma
• Hereditary RCC and germline testing-of-renal-cell-carcinoma
• Clinical presentation-of-renal-cell-carcinoma
• Staging (TNM classification) and prognosis-of-renal-cell-carcinoma
• Treatment principles-of-renal-cell-carcinoma
• Systemic therapy for metastatic clear cell RCC
• Second-line therapies-of-renal-cell-carcinoma
• Combined-modality therapies-of-renal-cell-carcinoma
• Tyrosine kinase inhibitors-of-renal-cell-carcinoma
• Immunotherapies-of-renal-cell-carcinoma
• mTOR inhibitors-of-renal-cell-carcinoma
• Non-clear cell histology-of-renal-cell-carcinoma